The 2nd World Congress on Controversies in Hematology (COHEM)



Dear Friends and Colleagues,

Following the great success of the 1st World Congress on Controversies in Hematology (COHEM) which attracted almost 500 participants from more than 60 countries, we are delighted to invite you to participate in the 2nd World Congress on Controversies in Hematology (COHEM) which will take place on September 6-8, 2012.

The 2nd COHEM Congress aims to circulate up to date information and to provide a unique opportunity for world leaders in the field to debate the most vital and contentious issues in benign and malignant Hematology. This thought-provoking academic dialogue will raise the most challenging current clinical and technological questions.

By allocating substantial time for discussions following each debate, audience members are encouraged to take a participating role in this influential academic dialogue. These exciting debates will highlight the key issues raised in 2011 and 2012 and provide clinicians with state-of-the-art recommendations regarding patient care.

We invite you to participate in the 2nd COHEM Congress and to take an active role in this innovative and interactive experience.

Topics:
Acute Myeloid Leukemia (AML)
• Acute Promyelocytic Leukemia (APL)
• Acute Lymphoid Leukemia (ALL)
• Chronic Lymphocytic Leukemia (CLL)
• Chronic Myeloid Leukemia (CML)
• Multiple Myeloma (MM)
• Myelodysplastic Syndrome (MDS)
• Myeloproliferative Disorders
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma (NHL)
• ITP, Coagulation Disorders
• Hemoglobinopathies & PNH
• Iron Overload
• Anemia of Chronic Disease
• Stem Cell Transplantation (SCT)
• Infections

+ show speakers and program
Has molecular characterization of cytogenetically normal AML been a major advance in the management of patients?
Moderator: TBA
Yes: B. Falini, Italy
No: C. Schiffer, USA
Discussion

17:00-17:45

17:00-17:05
17:05-17:15
17:15-17:25
17:25-17:45
Should the new genetic abnormalities and prognostic factors change our management of CLL patients?
Moderator: R. Foà, Italy
Yes: S. Stilgenbauer, Germany
No: G. Gaidano, Italy
Discussion


17:45-18:15
Coffee Break


18:15-19:30
TBA


19:30-21:00
Welcome Reception
Friday, September 7, 2012

Hall A

08:30-10:00
SESSION 2: AML

08:30-09:15

08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15
Should patients with high risk MDS (and AML in early relapse) proceed directly to allogeneic transplantation without prior induction chemotherapy?
Moderator: M.A. Sanz, Spain
Yes: A.K. Burnett, UK
No: P. Fenaux, France
Discussion

09:15-09:20

09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00
Should older patients with AML be considered for lower intensity approaches rather than 3 & 7?
Moderator: J. Esteve, Barcelona
Yes: J. Sierra, Spain
No: C. Schiffer, USA
Discussion

10:00-10:30
Coffee Break

10:30-12:00
SESSION 4: ALL


10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15
Should ‘pediatric’-like strategies be extended over the age of 35?
Moderator: D. Hoelzer, Germany
Yes: J.M. Ribera, Spain
No: J.P. Marie, France
Discussion

11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00
Can ALL be managed without chemotherapy / transplant?
Moderator: C. Schiffer, USA
Yes: R. Foà, Italy
No: D. Hoelzer, Germany
Discussion

12:00-13:00
Lunch Break

13:00-14:15
TBA

14:15-15:45
SESSION 6: MDS


14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00
Is iron chelation of importance in the management of myelodysplasia?
Moderator: G. Saglio, Italy
Yes: E. Rachmilewitz, Israel
No: A. Tefferi, USA
Discussion

15:00-15:45

15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45
After failure of hypomethylating agent-based therapy in myelodysplastic syndromes: which is the best strategy?
Moderator: C. Schiffer, USA
BMT: N. Kröger, Germany
Investigational drugs: V. Santini, Italy
Discussion


15:45-16:15
Coffee Break

16:15-17:45
SESSION 8: MPNs

16:15-17:00

16:15-16:20
16:20-16:30
16:30-16:40
16:40-17:00
Is the development of JAK 2 inhibitors an important advance in the treatment of MPNs?
Moderator: T. Barbui, Italy
Yes: TBA
No: A. Tefferi, USA
Discussion

17:00-17:45
17:00-17:05
17:05-17:15
17:15-17:25
17:25-17:45
Is the recommended hematocrit target in polycythemia vera evidence-based?
Moderator: R. Hehlmann, Germany
Yes: TBA
No: T. Barbui, Italy
Discussion

Hall B

08:30-10:00
SESSION 3: CLL


08:30-09:15
08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15
Monoclonal B-cell lymphocytosis: Much ado about nothing?
Moderator: R. Foà, Italy
Yes: E. Montserrat, Spain
No: A.C. Rawstron, UK
Discussion

09:15-10:00
09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00
Is the whole better than the sum of its parts? All ‘fit’ older patients should receive FCR.
Moderator: E. Montserrat, Spain
Yes: S. Stilgenbauer, Germany
No: R. Foà, Italy
Discussion

10:00-10:30
Coffee Break

10:30-12:00
SESSION 5: INDOLENT NON-HODGKIN LYMPHOMAS


10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15
Should all patients with follicular leukemia receive maintenance therapy?
Moderator: A. Hagenbeek, The Netherlands
Yes: TBA
No: E. Kimby, Sweden
Discussion

11:15-12:00

11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00
Is there a role of HDT-ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era?
Moderator: N. Kröger, Germany
Yes: B. Coiffier, France
No: A. Hagenbeek, The Netherlands
Discussion

12:00-13:00
Lunch Break

14:15-15:45
SESSION 7: HODGKIN'S DISEASE


14:15-15:00

14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00
Do we have one or two shots for cure in advanced Hodgkin’s disease? Kairos or Chronos?
Moderator: TBA
Pro Chronos: late intensification: J. Connors, Canada
Pro Kairos: early intensification: V. Diehl, Germany
Discussion

15:00-15:45
15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45
Should therapy for HD be modified by the results of the early PET?
Moderator: V. Diehl, Germany
Yes: P.L. Zinzani, Italy
No: A. Engert, Germany
Discussion


15:45-16:15
Coffee Break


16:15-17:45

SESSION 9: AGGRESSIVE LYMPHOMAS

16:15-17:00
16:15-16:20
16:20-16:30
16:30-16:40
16:40-17:00
Is there a role for RT in localized DLBCLs?
Moderator: C. Haioun, France
Yes: J. Yahalom, USA
No: TBA
Discussion

17:00-17:45
17:00-17:05
17:05-17:15
17:15-17:25
17:25-17:45
Is there a role for ASCT for the initial management of high risk DLBCLs?
Moderator: B. Coiffier, France
Yes: C. Haioun, France
No: J. Connors, Canada
Discussion



Saturday, September 8, 2012

Hall A

08:30-10:00
SESSION 10: CML

08:30-09:15

08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15
Are TKI sufficient for the treatment of CML, or should TKI be combined with other agents or treatment modalities?
Moderator: G. Saglio, Italy
Yes: R. Hehlmann, Germany
No: M. Baccarani, Italy
Discussion

09:15-10:00
09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00
Should patients treated with second line TKIs be considered for allo BMT?
Moderator: R. Hehlmann, Germany
Yes: E. Olavarria, Spain
No: J.L. Steegmann, Spain
Discussion


10:00-10:30
Coffee Break

10:30-12:00
SESSION 12: HEMOGLOBINOPATHIES


10:30-11:15

10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15
Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors?
Moderator: E. Rachmilewitz, Israel
Yes: E. Angelucci, Italy
No: MD. Cappellini, Italy
Discussion

11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00
Is there a rationale for treatment of sickle cell anemia except for acute complications?
Moderator: G. Rodgers, USA
Yes: S. Sheth, USA
No: J.L. Vives Corrons, Spain
Discussion

12:00-13:00
Lunch Break

13:00-14:15
TBA

14:15-15:45
SESSION 14: BIOMARKERS


14:15-15:00
14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00
Are the new molecular and cytogenetic markers useful for the management of MNPs? Moderator: A. Tefferi, USA
Yes: W. Vainchenker, France
No: TBA
Discussion

15:00-15:45

15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45
Is serum ferritin a sufficient marker for evaluation and monitoring treatment of iron overload?
Moderator: E. Rachmilewitz, Israel
Yes: A. Piga, Italy
No: Y. Cabantchik, Israel
Discussion

15:45-16:15
Coffee Break

16:15-18:00
PLENARY SESSION 16: DEBATES IN MM, CML & AML

16:15-16:50
16:15-16:20
16:20-16:30
16:30-16:40
16:40-16:50
MM - Cure versus control: Which is the best strategy?
Moderator: J.F. San-Miguel, Spain
Cure: B. Barlogie, USA
Control: M. Boccadoro, Italy
Discussion

16:50-17:25
16:50-16:55
16:55-17:05
17:05-17:15
17:15-17:25
Preferred 1st line treatment of CML: 2nd generation TKI or optimized Imatinib?
Moderator: J.L. Steegmann, Spain
2nd generation TKI: G. Saglio, Italy
Optimized Imatinib: R. Hehlmann, Germany
Discussion

17:25-18:00
17:25-17:30
17:30-17:40 17:40-17:50
17:50-18:00
Is there a possibility to cure APL without chemotherapy in the future?
Moderator: G. Saglio, Italy
Yes: M.A. Sanz, Spain
No: F. Lo-Coco, Italy
Discussion


Hall B

08:30-10:00
SESSION 11: MULTIPLE MYELOMA


08:30-09:15
08:30-08:35
08:35-08:45
08:45-08:55
08:55-09:15
Transplant in MM patients: Early versus late
Moderator: J.F. San-Miguel, Spain
Early: A. Nagler, Israel
Late: M. Boccadoro, Italy
Discussion

09:15-10:00
09:15-09:20
09:20-09:30
09:30-09:40
09:40-10:00
Is there a role for maintenance therapy?
Moderator: M. Boccadoro, Italy
Yes: A. Palumbo, Italy
No: J.F. San-Miguel, Spain
Discussion

10:00-10:30
Coffee Break

10:30-12:00
SESSION 13: INFECTIONS

10:30-11:15
10:30-10:35
10:35-10:45
10:45-10:55
10:55-11:15
Should anti-infection prophylaxis be given before / after BMT ?
Moderator: A. Nagler, Israel
Yes: TBA
No: E. Olavarria, Spain
Discussion

11:15-12:00
11:15-11:20
11:20-11:30
11:30-11:40
11:40-12:00
Are all the GFs the same?
Moderator: TBA
Yes: G. Gaidano, Italy
No: TBA
Discussion

12:00-13:00
Lunch Break

14:15-15:45
SESSION 15: COAGULATION


14:15-15:00

14:15-14:20
14:20-14:30
14:30-14:40
14:40-15:00
What should be the next step after failure of steroids in ITP – splenectomy versus Rituximab or TPO mimetics?
Moderator: MM. Samama, France
Splenectomy & Rituximab: R. Stasi, UK
TPO mimetics: J. Bussell, USA
Discussion

15:00-15:45
15:00-15:05
15:05-15:15
15:15-15:25
15:25-15:45
New anticoagulants: Monitoring or not Monitoring?
Mod: J. Bussell, USA
Monitoring: MM. Samama, France
Not Monitoring: A. Falanga, Italy
Discussion


6 Sep - 8 Sep 2012

Barcelona
Spain
meeting website